SenzaGen AB

Equities

SENZA

SE0010219626

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:48 2024-04-26 am EDT			5-day change	1st Jan Change
6.38 ^SEK	+0.31%		+2.90%	-12.36%

Mar. 25	Senzagen Receives Follow-Up Order Worth SEK 0.8 Million from the Global Chemicals Leader	CI
Mar. 22	SenzaGen AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

SenzaGen H2 - Continued growth and aligned with our expectations

February 15, 2024 at 01:57 am EST

Redeye provides an update in relation to SenzaGen’s H2 2023 report. We argue the report was solid and aligned with our expectations, where sales came in at SEK26.3m and EBIT at SEK-10.0m. We have made some estimate changes, resulting in an updated fair value range. However, our base case remains at SEK20.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about SenzaGen AB

Senzagen Receives Follow-Up Order Worth SEK 0.8 Million from the Global Chemicals Leader	Mar. 25	CI
SenzaGen AB Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
SenzaGen AB Reports Earnings Results for the Fourth Quarter Ended December 30, 2023	Feb. 14	CI
SenzaGen Books Additional Order for Non-animal Skin Sensitization Testing Tool	Jan. 10	MT
SenzaGen AB Receives A Follow-Up Order Worth SEK 1.5 Million for GARD®Skin for the Chemical Industry	Jan. 10	CI
SenzaGen Wins SEK2 Million Order for Biotech Product Testing	Dec. 18	MT
SenzaGen Secures SEK 1.7 Million Order from a New Global Biotech Industry Leader	Dec. 18	CI
SenzaGen Bags Chemicals Testing Contract	23-10-26	MT
Senzagen AB Secures Strategically Important Order from New Customer	23-10-26	CI
Transcript : SenzaGen AB - Special Call	23-10-18
SenzaGen Continues to Collaborate with RIFM in Non-Animal Photosensitization and Fragrance Safety	23-09-28	CI
SenzaGen AB Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
SenzaGen Signs Distribution Deals With French, Indian Companies	23-07-07	MT
SenzaGen Strengthens Market Presence with Expanded Distribution Channels	23-07-07	CI
SenzaGen AB Reports Consolidated Sales Results for the First Quarter of 2023	23-04-26	CI
SenzaGen AB Wins Order for GARD®skin Worth About SEK 1 Million from A New Chemicals Customer	23-02-23	CI
SenzaGen Seeks Acquisitions	23-02-16	CI
Transcript : SenzaGen AB, 2022 Earnings Call, Feb 16, 2023	23-02-16
SenzaGen AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI
SenzaGen AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI
Transcript : SenzaGen AB - Special Call	22-11-24
SenzaGen AB (OM:SENZA) acquired 100% stake in Toxhub S.R.L. for Ã‡0.3 million.	22-11-10	CI
Transcript : SenzaGen AB - Special Call	22-10-12
Transcript : SenzaGen AB, H1 2022 Earnings Call, Aug 18, 2022	22-08-18
SenzaGen AB Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-18	CI

Chart SenzaGen AB

Duration

Period

More charts

Company Profile

SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for SenzaGen AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
SENZAGEN AB	-12.36%	14.08M
EXACT SCIENCES CORPORATION	-20.45%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B
GUARDANT HEALTH, INC.	-35.86%	2.11B
BGI GENOMICS CO., LTD.	-17.21%	2.08B
VERACYTE, INC.	-29.81%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B
SEEGENE, INC.	-4.37%	733M
CAREDX, INC	-37.00%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	383M

Bio Diagnostics & Testing